May 2019: AGITG Trial Updates
ALT-GIST results to be presented at ASCO The preliminary results of the phase II ALT-GIST study will be presented... Read More
Report from the COSA Cancer Survivorship Conference: Jan Mumford & Robin Mitchell
The Clinical Oncology Society of Australia (COSA) Cancer Survivorship Conference was held from 28-29 March. The event hosted... Read More
AGITG Joint Working Party Meeting 10 May 2019
AGITG Joint Working Party Meeting 10 May 2019 May 22, 2019 Lower GI Working Party Trial Updates SPAR recruitment is underway... Read More
AGITG Outstanding Site Award
Clinical trial sites actively involved in AGITG Studies are invited to submit a brief application of 500 words... Read More
AGITG Lower GI Working Party: 13 March 2019
APOLLO1: Australian Peritoneal Organoid guided therapy to Lengthen Life in patients without Opportunity for Cure: a pilot trial. This... Read More
April 2019: Trial news
The DYNAMIC Studies AGITG currently has three studies investigating ctDNA in gastro-intestinal cancers. The three trials will help determine... Read More
The first Japanese site in an AGITG trial opens for INTEGRATE II
The first AGITG trial site in Japan has opened for the INTEGRATE II study in gastro-oesophageal cancer. National Cancer... Read More
John Zalcberg OAM Award Open for Applications
The John Zalcberg OAM Award for Excellence in AGITG Research Pictured – L to R: Professor Tim Price AGITG... Read More
Upper GI Working Party Meeting: 13 February 2019
Concept Updates from previous meetings: NAP CAPABIL: Single arm phase II trial of NAB-paclitaxel in combination with capecitabine as second-line... Read More
How the GI Cancer Institute’s research is developed
The GI Cancer Institute’s research and clinical trials are developed through a robust, scientific process. The studies we... Read More
Professor Tim Price to lead the 2019 Gutsy Southern Alps Challenge in New Zealand
Professor Tim Price, Chair of the GI Cancer Institute, will lead the Gutsy Southern Alps Challenge in New... Read More
Our Research Priorities: What is key to the future of research?
During 2017 our Board of Directors and management created a revised Strategic Plan for the organisation and its... Read More
Gastro-intestinal surgeons receive Australia Day honours
Excellence in gastro-intestinal (GI) cancer research and treatment has been recognised on the Australia Day 2019 Honours List,... Read More
Cancer drugs made available on PBS for gastro-intestinal cancer patients
The Department of Health has announced on Saturday 1 December that five new cancer listings have been made... Read More
Interview: Clinical Research Fellow Dr David Lau
Dr David Lau is three months into his fellowship at Royal Marsden Hospital, London. “It has been incredible,” he... Read More
CommNETs Clinical Trial Workshop: 8-9 December
The Commonwealth Neuroendocrine Tumour Group (CommNETs) held its first Clinical Trials Development Workshop in Hong Kong on... Read More
Centre for Community-Driven Research: Patient Events & the PEEK Study
The AGITG is working with the Centre for Community-Driven Research (http://www.cc-dr.org/au), a charity that aims to understand... Read More
How AGITG research is developed
The AGITG’s research and clinical trials are developed through a robust, scientific process. The studies we conduct are based on our strategic research priorities, which identify the areas of greatest need for patients. Our priorities include a focus on rare and underfunded cancers and areas where patients have few treatment... Read More
Targeted therapy for metastatic colorectal cancer: Slide resource for members
A slide set has been produced by Dr Matthew Burge, A/Prof Niall Tebbutt and Prof Tim Price, titled... Read More
CONTROL NETs accrues final patients
The CONTROL NETs trial in neuroendocrine tumours (NETs) has finished patient accrual and is now in follow-up. NETs are... Read More